Advertisement

Alpha- and beta-synuclein expression in Parkinson disease with and without dementia

  • Katrin Beyer
    Correspondence
    Corresponding author at: Servicio de Anatomía Patológica, Hospital Universitario Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain. Tel.: +34 93 497 88 53; fax: +34 93 497 88 43.
    Affiliations
    Servicio de Anatomía Patológica, Hospital Universitario Germans Trias i Pujol, Universidad Autonoma de Barcelona, Spain

    ICS Institute of Neuropathology, Barcelona, Spain
    Search for articles by this author
  • Lourdes Ispierto
    Affiliations
    Servicio de Neurología, Hospital Universitario Germans Trias i Pujol, Universidad Autonoma de Barcelona, Spain
    Search for articles by this author
  • Pilar Latorre
    Affiliations
    Servicio de Neurología, Hospital Universitario Germans Trias i Pujol, Universidad Autonoma de Barcelona, Spain
    Search for articles by this author
  • Eduardo Tolosa
    Affiliations
    Servicio de Neurología, Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, Universidad de Barcelona, Spain
    Search for articles by this author
  • Aurelio Ariza
    Affiliations
    Servicio de Anatomía Patológica, Hospital Universitario Germans Trias i Pujol, Universidad Autonoma de Barcelona, Spain

    ICS Institute of Neuropathology, Barcelona, Spain
    Search for articles by this author

      Abstract

      Parkinson disease (PD) is the most important movement disorder and about 50% of patients develop dementia over the time. PD belongs to the group of Lewy body disorders. Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the pathogenesis of PD. Beta-synuclein (BS) inhibits AS aggregation in vitro and in vivo and has been shown to interact directly with AS regulating its functionality and preventing its oligomerization. Recently, we have described a molecular subgroup of DLB characterized by the drastic BS reduction in cortical areas. In this study we have analyzed the expression of two BS transcripts and the main AS transcript SNCA140, in frozen samples of three brain areas, temporal cortex, caudate nucleus and pons, from patients with PD and PDD in comparison with controls. Relative mRNA expression was determined by real-time PCR with SybrGreen, neuron-specific-enolase as housekeeping gene and the deltadeltaCt method. The most important difference in BS and AS mRNA expression between PD and PDD was found in the caudate nucleus, where BS mRNA was overexpressed in PD and AS mRNA diminished in PDD. Our findings provide new insights into the pathogenesis of dementia in PD, indicating that differential BS and AS expression in the caudate nucleus may represent one of the molecular mechanisms involved in these complex diseases.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aarsland D.
        • Andersen K.
        • Larsen J.P.
        • Lolk A.
        • Kragh-Sørensen P.
        Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.
        Arch Neurol. 2003; 60: 387-392
        • Goetz C.G.
        • Emre M.
        • Dubois B.
        Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis.
        Ann Neurol. 2008; 64: S81-S92
        • Kalaitzakis M.E.
        • Pearce R.K.
        The morbid anatomy of dementia in Parkinson's disease.
        Acta Neuropathol. 2009; 118: 587-598
        • Burn D.J.
        • Rowan E.N.
        • Allan L.M.
        • Molloy S.
        • O'Brien J.T.
        • McKeith I.G.
        Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies.
        J Neurol Neurosurg Psychiatry. 2006; 77: 585-589
        • Spillantini M.G.
        • Crowther R.A.
        • Jakes R.
        • Hasegawa M.
        • Goedert M.
        alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.
        Proc Natl Acad Sci USA. 1998; 95: 6469-6473
        • Braak H.
        • Braak E.
        Diagnostic criteria for neuropathological assessment of Alzheimer's disease.
        Neurobiol Aging. 1997; 18: S85-S88
        • Jellinger K.A.
        A critical reappraisal of current staging of Lewy-related pathology in human brain.
        Acta Neuropathol. 2008; 116: 1-16
        • Jellinger K.A.
        A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.
        Biochim Biophys Acta. 2009; 1792: 730-740
        • Ferman T.J.
        • Boeve B.F.
        Dementia with Lewy bodies.
        Neurol Clin. 2007; 25: 741-760
        • Jellinger K.A.
        • Attems J.
        Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?.
        Acta Neuropathol. 2006; 112: 253-260
        • Jellinger K.A.
        Striatal beta-amyloid deposition in Parkinson disease with dementia.
        J Neuropathol Exp Neurol. 2008; 67: 484-485
        • Kalaitzakis M.E.
        • Graeber M.B.
        • Gentleman S.M.
        • Pearce R.K.
        Striatal beta-amyloid deposition in Parkinson disease with dementia.
        J Neuropathol Exp Neurol. 2008; 67: 155-161
        • Shults C.W.
        Lewy bodies.
        Proc Natl Acad Sci USA. 2006; 103: 1661-1668
        • Kramer M.L.
        • Schulz-Schaeffer W.J.
        Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.
        J Neurosci. 2007; 27: 1405-1410
        • Chandra S.
        • Gallardo G.
        • Fernández-Chacón R.
        • Schlüter O.M.
        • Südhof T.C.
        Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.
        Cell. 2005; 123: 383-396
        • Cooper A.A.
        • Gitler A.D.
        • Cashikar A.
        • Haynes C.M.
        • Hill K.J.
        • Bhullar B.
        • et al.
        Alpha-synuclein blocks ER-golgi traffic and Rab1 rescues neuron loss in Parkinson's models.
        Science. 2006; 313: 324-328
        • Uversky V.N.
        • Li J.
        • Souillac P.
        • Millett I.S.
        • Doniach S.
        • Jakes R.
        • et al.
        Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
        J Biol Chem. 2002; 277: 11970-11978
        • Sung Y.H.
        • Eliezer D.
        Residual structure, backbone dynamics, and interactions within the synuclein family.
        J Mol Biol. 2007; 372: 689-707
        • Beyer K.
        • Domingo-Sàbat M.
        • Santos C.
        • Tolosa E.
        • Ferrer I.
        • Ariza A.
        The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.
        Brain. 2010; 133: 3724-3733
        • Maroteaux L.
        • Campanelli J.T.
        • Scheller R.H.
        Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.
        J Neurosci. 1988; 8: 2804-2815
        • Park J.Y.
        • Lansbury Jr., P.T.
        Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
        Biochemistry. 2003; 42: 3696-3700
        • Tsigelny I.F.
        • Bar-On P.
        • Sharikov Y.
        • Crews L.
        • Hashimoto M.
        • Miller M.A.
        • et al.
        Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.
        FEBS J. 2007; 274: 1862-1877
        • Hashimoto M.
        • Rockenstein E.
        • Mante M.
        • Mallory M.
        • Masliah E.
        beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.
        Neuron. 2001; 32: 213-223
        • Snyder H.
        • Mensah K.
        • Hsu C.
        • Hashimoto M.
        • Surgucheva I.G.
        • Festoff B.
        • et al.
        beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein.
        J Biol Chem. 2005; 280: 7562-7569
        • McKeith I.G.
        • Dickson D.W.
        • Lowe J.
        • Emre M.
        • O'Brien J.T.
        • Feldman H.
        • et al.
        Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.
        Neurology. 2005; 65: 1863-1872
        • Braak H.
        • Del Tredici K.
        • Rüb U.
        • de Vos R.A.
        • Jansen Steur E.N.
        • Braak E.
        Staging of brain pathology related to sporadic Parkinson's disease.
        Neurobiol Aging. 2003; 24: 197-211
        • Braak H.
        • Braak E.
        Neuropathological stageing of Alzheimer-related changes.
        Acta Neuropathol. 1991; 82: 239-259
        • Durrenberger P.F.
        • Fernando S.
        • Kashefi S.N.
        • Ferrer I.
        • Hauw J.J.
        • Seilhean D.
        • et al.
        Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study.
        J Neuropathol Exp Neurol. 2010; 69: 70-81
        • Fuchs J.
        • Tichopad A.
        • Golub Y.
        • Munz M.
        • Schweitzer K.J.
        • Wolf B.
        • et al.
        Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain.
        FASEB J. 2008; 22: 1327-1334
        • Schmittgen T.D.
        • Livak K.J.
        Analyzing real-time PCR data by the comparative C(T) method.
        Nat Protoc. 2008; 3: 1101-1108
        • Israeli E.
        • Sharon R.
        Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein.
        J Neurochem. 2009; 108: 465-474
        • Schulz-Schaeffer W.J.
        The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.
        Acta Neuropathol. 2010; 120: 131-143
        • Jensen P.H.
        • Hager H.
        • Nielsen M.S.
        • Hojrup P.
        • Gliemann J.
        • Jakes R.
        alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356.
        J Biol Chem. 1999; 274: 25481-25489
        • Masliah E.
        • Rockenstein E.
        • Veinbergs I.
        • Sagara Y.
        • Mallory M.
        • Hashimoto M.
        • et al.
        beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
        Proc Natl Acad Sci USA. 2001; 98: 12245-12250
        • Pletnikova O.
        • West N.
        • Lee M.K.
        • Rudow G.L.
        • Skolasky R.L.
        • Dawson T.M.
        • et al.
        Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
        Neurobiol Aging. 2005; 26: 1183-1192
        • Ferrer I.
        • Santpere G.
        • van Leeuwen F.W.
        Argyrophilic grain disease.
        Brain. 2008; 131: 1416-1432
        • Jellinger K.A.
        The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease.
        J Neurol Neurosurg Psychiatry. 1988; 51: 540-543
        • Mattila P.M.
        • Röyttä M.
        • Torikka H.
        • Dickson D.W.
        • Rinne J.O.
        Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease.
        Acta Neuropathol. 1998; 95: 576-582
        • Jellinger K.A.
        The neuropathologic substrate of Parkinson disease dementia.
        Acta Neuropathol. 2010; 119: 151-153